Department of Biomedical Engineering, University of Alberta, Edmonton, AB T6G 2V2, Canada.
Biotechnol Lett. 2012 May;34(5):989-93. doi: 10.1007/s10529-012-0858-y.
Monocyte-based gene therapies in cancer have been hampered by either the resistance of these cells to non-viral molecular delivery methods or their poor trafficking to the tumor site after their ex vivo manipulations. Magnetic nanoparticles (MNP)-loaded genetically engineered monocytes can efficiently delivered to tumor site by external magnetic field, but they are not ideal delivery tools due to their spherical shape. Hence, we have investigated the cellular uptake efficiency and cytotoxicity of fluorescein isothiocyanate (FITC)-labelled magnetic carbon nanotubes (FITC-mCNT) in human monocytic leukemia cell line THP-1 for application in cell-based gene therapy against cancer. Uptake of FITC-mCNT into THP-1 cells reached 100% only 1 h after the delivery. Confocal imaging confirmed that FITC-mCNT entered the cell cytoplasm and even into the nucleus. FITC-mCNT uptake did not compromise cell viability. This delivery system might therefore enhance cell-based cancer gene therapies.
基于单核细胞的癌症基因治疗受到这些细胞对非病毒分子传递方法的抗性或其在体外操作后向肿瘤部位的不良迁移的阻碍。负载磁性纳米颗粒 (MNP) 的基因工程单核细胞可以通过外部磁场有效地递送到肿瘤部位，但由于它们的球形形状，它们不是理想的递药工具。因此，我们研究了荧光素异硫氰酸酯 (FITC) 标记的磁性碳纳米管 (FITC-mCNT) 在人单核白血病细胞系 THP-1 中的细胞摄取效率和细胞毒性，以应用于基于细胞的癌症基因治疗。在递药 1 小时后，FITC-mCNT 进入 THP-1 细胞的摄取率达到 100%。共聚焦成像证实 FITC-mCNT 进入了细胞质，甚至进入了细胞核。FITC-mCNT 的摄取并不影响细胞活力。因此，这种递药系统可能增强基于细胞的癌症基因治疗。
